In the present study, circulating proportions of CD8 + T (Tc) cell subsets, including IL-17 (Tc17) and IL-10 (Tc10) producing cells, were assessed in relapsing-remitting MS (RRMS) patients and a possible effect of beta interferon (IFN-β), glatiramer acetate (GA), and vitamin D (VitD) on these cell subsets was investigated. We show that both Tc17 and Tc10 cell fractions are elevated in the circulation of RRMS patients in remission compared to healthy subjects and that these Tc subsets remain unaffected by current immune modulating regimens.
Introduction
Multiple sclerosis (MS) is considered to be a T cell mediated autoimmune disease. Although research focused mainly on CD4 + T helper (Th) cells, CD8 + cytotoxic T (Tc) cells may be importantly involved in MS pathogenesis as well. It was demonstrated that adoptively transferred myelin specific Tc cells could induce experimental autoimmune encephalomyelitis (EAE) (Huseby et al., 2001; Sun et al., 2001 ), the animal model for MS. Certain MHC class I alleles were identified as MS disease risk alleles (reviewed by Martin, 2008) and MHC class I expression was higher on astrocytes and oligodendrocytes in MS lesions compared to normal brain tissue (Hoftberger et al., 2004) . Tc cells could be detected in MS brain lesions and they even outnumbered Th cells. These Tc cells were found in the vicinity of damaged oligodendrocytes and myelin containing antigen presenting cells (Neumann et al., 2002; Serafini et al., 2006) . In addition, the intralesional Tc cells, as well as Tc cells in the cerebrospinal fluid (CSF), are clonally expanded, suggesting antigen specific reactivity (Babbe et al., 2000; Jacobsen et al., 2002) .
Together, these data suggest active involvement of Tc cells in MS pathogenesis. Like Th cells, Tc cells can be divided into different subsets based on their cytokine profile. In MS patients, research focused mainly on peripheral IFN-γ + and IL-4 + Tc cells (Tc1 and Tc2, respectively).
Studies regarding the Tc1 cell percentages show contradictory results, whereas studies regarding the Tc2 cell fractions show no difference between MS patients and healthy controls (Becher et al., 1999; Inoges et al., 1999; Furlan et al., 2000; Killestein et al., 2001; Ochi et al., 2001; Sepulcre et al., 2005) . Recently, an IL-17 producing cell subset within the Tc cell compartment (Tc17) was identified. Interestingly, Wang et al. showed that Tc17 cells are increased in the peripheral blood of relapsing-remitting MS patients (RRMS) (Wang et al., 2011) and more than 70% of the Tc cells in MS brain tissue are IL-17 positive (Tzartos et al., 2008) . Next to Tc17 cells, IL-10 producing Tc (Tc10) cells have been described as cells important in tissue protection during a viral infection (reviewed by Zhang and Bevan, 2011) . These cells might also be importantly involved in controlling inflammation in MS patients.
In this study, we investigated the Tc cell compartment, including Tc17 and Tc10 cells, in healthy volunteers and RRMS patients in remission and during a relapse. We measured fractions of Tc cell subsets and investigated the effects of first line immune modulating treatments for RRMS, i.e. beta interferon (IFN-β) and glatiramer acetate (GA). Moreover, we examined the effect of high dose vitamin D supplementation, as add-on therapy to IFN-β, on Tc10 and Tc17 cell fractions.
Methods

Patients and blood sampling
In total, 73 RRMS patients were included in this study. Sixty-four RRMS patients were enrolled from the Academic MS Center at Orbis Medical Center (Sittard, The Netherlands), and 9 RRMS patients were enrolled from the MS Center at Amphia Hospital (Breda, The Netherlands). RRMS was defined by the revised McDonald criteria (Polman et al., 2011) . Only RRMS patients with a disease duration b 6 years were included and RRMS patients in remission had to be relapse free for at least 6 weeks. Written informed consent was obtained from each study subject and the study was approved by the regional ethical committee 'Atrium-Orbis-Zuyd', 'Local Advisory Board on Scientific Research' of Orbis Medical Center and 'the medical ethical committee of Amphia' of Amphia Hospital.
Tc cell fractions in HC and MS patients in remission or during a relapse and the effects of IFN-β and GA were studied in a crosssectional cohort study in which 59 RRMS patients and 30 HC were enrolled. Gender and age of the MS patients matched that of the HC. Characteristics of these populations are given in Table 1 . Forty-seven MS patients were in disease remission and were either using no immune modulatory drugs (n = 16), or were treated with IFN-β 1a/1b (n = 18) or GA (n = 13). Twelve RRMS patients were included while having a relapse. None of these patients were on immune modulating therapy. A relapse was defined as occurrence of new symptoms which lasted at least 24 h and required treatment with intravenous methylprednisolone. Blood samples were retrieved before methylprednisolone infusion.
The association of vitamin D with different Tc cell subsets was studied in the above described cross-sectional cohort and the influence of vitamin D supplementation on the composition of the Tc cell compartment was studied in 14 RRMS patients who received a daily dose of 20,000 IU vitamin D 3 for 12 weeks. All 14 supplemented patients were in remission and were treated with IFN-β 1a/1b. Blood samples for T cell phenotyping were retrieved at baseline and at 12 weeks. Detailed population characteristics are described by Smolders et al. (2010b) .
Serum 25(OH)D assessment
Serum samples were stored directly after sampling until analysis at -20°C. A radioimmunoassay kit (Immunodiagnostic Systems, Boldon, UK) was used to determine serum 25-hydroxyvitamin D (25(OH)D) levels (representing the vitamin D status).
Intracellular flow cytometry
Ficoll density gradient centrifugation (Histopaque; Sigma Aldrich, Zwijndrecht, The Netherlands) was used to isolate peripheral blood mononuclear cells (PBMC). To assess the intracellular CD8 + T cell cytokine profile, PBMC were stimulated with 1 μg/mL calcium ionomycine (Sigma Aldrich) and 50 ng/mL PMA (Sigma Aldrich) for 5 h. Monensin (BD Biosciences, Breda, The Netherlands) was added simultaneously to block cytokine secretion. After stimulation, cells were stained extracellularly with anti-CD3-horizon V450 and anti-CD8-APC-H7 (both BD Biosciences). Next, the cells were fixed and permeabilized using fixation/permeabilization buffer (BD Biosciences). Cells were then stained intracellularly with anti-IFN-γ-FITC (BD Biosciences), anti-IL-4-PE, anti-IL-10-APC and anti-IL-17A-PerCP-Cy5.5 (all Biolegend, Uithoorn, The Netherlands). Samples were acquired on a FACS Canto II flow cytometer (BD Biosciences) and data analysis was performed using the FACS Diva software (BD Biosciences). On average 10,000 events within the CD8 + T cell gate were acquired. A representative example of our gating strategy and specificity of the staining is illustrated in Fig. 1 .
Statistics
Statistical analysis was performed with Statistical Package for Social Sciences version 17.0 software (SPSS Inc., Chicago, IL). Continuous data are given as median with corresponding interquartile range (IQR). Differences in continuous variables between groups were tested using the Mann-Whitney U test. Associations between the vitamin D status and the different cytokine producing CD8 + T cells were assessed with the Spearman correlation. Paired variables were analyzed with the Wilcoxon Signed Ranks test. A p-value b0.05 was considered statistically significant. Fig. 4E-F) . The double producing Tc cell frequencies at baseline did not differ from these Tc cell frequencies 12 weeks after vitamin D 3 supplementation (data not shown).
Results
The fraction cytokine producing CD8 + T cell subsets in RRMS patients
Discussion
In the present study, we show first that Tc10 and Tc17 Tc cell percentages are higher in untreated RRMS patients in remission compared to HC. Second, percentages of the different Tc cell subsets were similar between untreated RRMS patients in remission and during a relapse. Third, IFN-β-treated RRMS patients in remission showed lower Tc1 cell percentages, but no different Tc2, Tc10 or Tc17 cell percentages, compared to untreated RRMS patients in remission. GA treatment did not affect any of the Tc cell subsets. Fourth, vitamin D supplementation, as add-on to IFN-β therapy, did not influence fractions of the different Tc cell subsets. Tc cells are T cells with cytotoxic properties which are especially important in controlling viral infections (reviewed by Zhang and Bevan, 2011) . Epstein-Barr virus (EBV), a risk factor for MS, might be a pivotal link between Tc cells and MS (Ascherio and Munger, 2007 ). An in vitro study showed that Tc cells are able to induce apoptosis in oligodendrocytes (Jurewicz et al., 1998) . This could eventually result in a decreased myelinization of the axons and this might add to MS pathogenesis. Next to the classical cytotoxic function, Tc cells might exert helper functions through cytokine secretion, which could play an important role in MS as well. In addition, cytotoxicity and cytokine production can be produced in the same cell. Tc1 cells seem to produce next to IFN-γ also perforin, while Tc17 cells seem to be unable to produce this effector molecule. In MS, little research has focused on cytokine producing Tc cell subsets and these studies preferentially addressed Tc1 and Tc2 cells. Therefore, the main focus of the present study was on Tc10 and Tc17 cell subsets, since these subsets may have regulatory and pathogenic potential, respectively.
Our results show that untreated RRMS patients in remission had an expanded Tc17 cell population compared to healthy controls, while the percentage of this cell subset did not differ between untreated RRMS patients in remission and during a relapse. Wang et al. showed an elevated Tc17 cell fraction in MS patients during a relapse compared to healthy controls, but did not include MS patients in remission (Wang et al., 2011) . In addition, a recent study showed an increased Tc17 cell fraction in the CSF of clinically isolated syndrome and early MS patients, but not in the periphery (Huber et al., 2013) . The discrepancy between this and our study could be explained by the differences in patient cohorts. Huber et al. included patients during their first clinical symptoms, while our patients were in remission and would have, on average, a longer disease duration. Moreover, their control cohort consisted of patients with non-infectious headache, while we included HC. Tc17 cells can, like their T helper counterpart (Th17 cells), be expected to play a pathogenic role in MS. The observation that >70% of Tc cells in MS lesions express IL-17 supports this. Moreover, recently Tc17 cells have been shown to be important in the migration and accumulation of Th cells into the central nervous system (CNS) and therefore seem essential in EAE induction (Huber et al., 2013) . To further investigate the role of these cells in the pathogenesis, more functional studies should be performed. It would be interesting to investigate the Tc17 cell responses to a probably more representative antigen for MS, like myelin oligodendrocyte glycoprotein or myelin basic protein.
Next to Tc17 cells, we observed an expanded Tc10 cell population in untreated RRMS patients in remission. In contrast, Killestein et al. observed a reduction in Tc10 cell percentages in RRMS patients (Killestein et al., 2001) . The discrepancy between the two studies might be explained by the used patient materials (freshly isolated PBMC in our study and thawed PBMC in Killestein's study). IL-10 + T cell percentages might be more susceptible to differences in activation conditions, since we recently showed that monensin reduced IL-10 + T cell percentages while it enhanced the other cytokine producing T cell fractions (Muris et al., 2012) . In line with this, we speculate that Tc10 cell percentages can be affected by a freezing-thawing cycle. Indeed, cytokine secretion or the fraction of cytokine positive cells might differ between fresh and thawed PBMC (Mallone et al., 2011) . The results of the present study suggest that the immune system tries to counterbalance the increase in pro-inflammatory cells by expanding the Tc10 fraction. Tc10 cells have been described to be regulatory cells which are important in protection from tissue damage during infections (reviewed by Zhang and Bevan, 2011) . We speculate that this function also exists during inflammation in autoimmune diseases and that the expanded Tc10 cell population could protect the brain tissue from damage in MS. This might be insufficient during disease exacerbation. Th cells can express multiple cytokines simultaneously, even cytokines which have been assigned to different Th cell subpopulations. These double producing cells might exert distinct functions (Boniface et al., 2010; Zielinski et al., 2012) . Also, Th17 cells have been described to be pathogenic cells in EAE, while Th cells producing both IL-17 and IL-10 seem to be non-pathogenic (McGeachy et al., 2007) . This might also be true for Tc cells. Therefore, we assessed 3 different double producing Tc cell subsets, i.e. IL-10 Our results showed that the frequency of the first is too low for reliable analysis, whereas the latter two Tc subsets were elevated in untreated RRMS patients in remission. The low cell frequencies of these double producing Tc cells implicate, however, that the findings of these subsets in our cohort should be approached with caution. Future studies investigating double producing Tc cells should be more accurately designed for this purpose and if possible elucidate the function of these cells.
GA and IFN-β are first line immune modulatory drugs, which have been shown to reduce the relapse rate (PRISMS, 1998; Comi et al., 2001) . Studies indicate that the induction of anti-inflammatory and regulatory immune cells and the inhibition of pro-inflammatory cells might contribute to the beneficial effects of these therapies (reviewed by Goodin, 2005; Lalive et al., 2011) . In the present study, we only observed a reduction in the Tc1 cell fraction in the IFN-β-treated RRMS population. This is in agreement with previous studies (Becher et al., 1999; Franciotta et al., 2003; Mei et al., 2006) . The Tc1 signature cytokine, IFN-γ, is involved in various immune stimulating processes (Pouly et al., 2000) . These observations suggest a pathogenic role for this Tc cell subset and the observed reduction in this subset might contribute to the clinical effect of IFN-β. The clinical effect of GA does not seem to be due to modulation of Tc cell subset numbers. However, a local effect of IFN-β or GA cannot be excluded. It is possible that IFN-β and GA do not affect circulating Tc cell percentages, but instead influence their function, e.g. cytokine secretion, prevent pathogenic Tc cells from entering the CNS or act locally on Tc cells, or act on other pathogenic T cells. Next to first line medication, vitamin D is being advocated as a possible add-on therapy because of its immune modulatory properties (Smolders et al., 2010a . In autoimmune diseases, vitamin D skews the immune system towards a more anti-inflammatory profile (reviewed by Peelen et al., 2011) . Studies investigating the effects of vitamin D on Tc cells are limited. Veldman et al. showed that Tc cells express higher levels of the vitamin D receptor compared to Th cells (Veldman et al., 2000) . However, vitamin D has been shown to prevent EAE independently of Tc cells (Meehan and DeLuca, 2002) . Nonetheless, vitamin D might have a beneficial effect on Tc cells in MS patients. Interestingly, Lysandropoulos et al. showed in vitro that vitamin D was able to reduce IFN-γ and TNF-α secretion when Tc cells were stimulated with either an EBV-peptide or anti-CD3 and anti-CD28 antibodies (Lysandropoulos et al., 2011) . Our data do not show an association of the different Tc cell subsets and the vitamin D status in HC and RRMS patients in remission. Recently, Stewart et al. showed that MS patients with IFN-β treatment with a higher vitamin D status had a reduced relapse rate (Stewart et al., 2012) . This suggests a synergistic effect of vitamin D and IFN-β treatment, which might also be true for effects on the immune system. Therefore, we investigated the associations in the different treatment groups. However, we did not observe an association between the vitamin D status and the different Tc cell subsets in RRMS patients in remission with IFN-β treatment nor in the patients without treatment. Also, high dose vitamin D supplementation in RRMS patients with IFN-β treatment did not affect these Tc cell frequencies. In RRMS patients in remission with GA, we only observed a positive association between the vitamin D status and Tc10 cell percentages. This might indicate that vitamin D and GA have a synergistic effect on Tc10 cells.
This paper provides new insights in the frequency of circulating Tc10 and Tc17 cells in RRMS patients in remission and during a relapse. Furthermore, as far as we know, this is the first paper that assessed the effect of first line treatment and vitamin D on Tc10 and Tc17 cells in RRMS patients directly ex vivo. The present study has some short comings. First, except for the vitamin D supplementation, our study had a cross-sectional design, which gives no information on causality. Second, we only assessed cells in the periphery and not in CSF or brain tissue. Third, we investigated Tc cell percentages, which do not give information on the amount of cytokines secreted or other functional properties of these cells.
In conclusion, untreated RRMS patients in remission have an augmented Tc10 and Tc17 cell fraction in the circulation, while during a relapse the Tc cell subset percentages are similar to the percentages of the patients in remission. Whether Tc10 and Tc17 cells are actively involved in the pathogenesis of RRMS remains to be determined. If so, new therapeutic modalities will be required since our data show that current first line medication does not affect the relative presence of these Tc cell subsets.
